炎症性肠病直肠癌患者术前放化疗的急性毒性与手术并发症
该研究基于荷兰病理登记库(PALGA)1991年至2010年数据,纳入161例炎症性肠病(IBD)合并直肠癌患者,其中66例(41%)接受术前治疗(短程放疗32例、长程放疗13例、放化疗21例)。结果显示≥3级急性毒性在短程放疗组为0.0%、长程放疗组为7.7%、放化疗组为28.6%(p=0.004),≥3级术后30天并发症总体发生率为28.1%且与术前治疗类型无关,不支持IBD患者因担心过度副作用而放弃标准术前治疗的顾虑。
要点
- IBD直肠癌患者术前短程放疗≥3级急性毒性为0.0%。
- 放化疗组≥3级急性毒性28.6%,显著高于短程放疗组(p=0.004)。
- ≥3级术后30天并发症率28.1%,与术前治疗类型无关。
核心结论
- IBD直肠癌患者接受标准术前治疗未出现过高的毒性或术后并发症率,支持对病情相对惰性的IBD患者使用标准术前治疗(尤其短程放疗)。
- 对活动性IBD患者需谨慎,因活动性肠道炎症的确切影响无法通过回顾性研究确定。
研究设计与样本
- 回顾性队列研究,检索荷兰病理登记库(PALGA)1991年1月至2010年5月间IBD合并直肠癌患者,复核组织病理学与临床病历以确认IBD诊断并评估临床病理特征。
- 共纳入161例患者,其中66例(41%)接受术前治疗。
主要发现
- 66例接受术前治疗的患者中,短程放疗32例、长程放疗13例、放化疗21例。
- ≥3级急性毒性发生率分别为短程放疗0例(0.0%)、长程放疗1例(7.7%)、放化疗6例(28.6%),p=0.004。
- 治疗时10.5%的患者使用全身性糖皮质激素。
- ≥3级术后30天并发症总体发生率为28.1%,与术前治疗类型无关。
关键数值与推荐
- ≥3级急性毒性:短程放疗0.0%、长程放疗7.7%、放化疗28.6%(p=0.004)。
- ≥3级术后30天并发症总体发生率28.1%,与术前治疗类型无关联。
- 治疗时全身性糖皮质激素使用率10.5%。
临床怎么用
- 对病情相对惰性的IBD合并直肠癌患者,可考虑标准术前治疗,尤其短程放疗。
- 对活动性IBD患者应谨慎决策,因活动性肠道炎症对毒性的影响尚未明确。
- 建议开展前瞻性研究评估活动性IBD对盆腔照射急性和晚期毒性的影响。
局限性
- 回顾性研究设计,无法确定活动性IBD对急性及晚期毒性的确切影响。
- 活动性IBD患者的确切影响无法通过回顾性方式确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Preoperative therapy reduces local recurrences and may facilitate surgery in rectal cancer patients. However, in patients with inflammatory bowel disease (IBD) this treatment is often withheld due to the perceived risk of excessive side-effects, even though evidence is limited. The purpose of this study is to investigate the effects of preoperative therapy on acute toxicity and post-operative complications in IBD patients with rectal cancer. METHODS: The Dutch pathology registry (PALGA) was searched for patients with IBD and rectal cancer treated between January 1991 and May 2010. Histopathology and clinical charts were reviewed to confirm IBD diagnosis and evaluate clinical and pathological characteristics. RESULTS: Out of 161 patients, 66 received preoperative therapy (41%), including short-course radiation therapy (SC-RT), long course radiation therapy (LC-RT), and chemoradiation therapy (CRT) in 32, 13, and 21 patients respectively. Grade≥3 acute toxicity occurred in 0 patients (0.0%), 1 patient (7.7%), and 6 patients (28.6%) respectively (p=0.004). Systemic corticosteroids were used by 10.5% of patients at time of treatment. Grade≥3 post-operative 30-day complication rate (28.1% overall) was not associated with type of preoperative therapy. CONCLUSION: Results did not show excessive rates of toxicity or post-operative complications and support the use of standard preoperative therapies for rectal cancer (especially SC-RT) in IBD patients with relatively indolent disease. Caution is warranted in patients with active IBD, since the exact impact of active bowel inflammation could not be determined retrospectively. Prospective studies should investigate the influence of active IBD on acute and late toxicity in patients receiving pelvic irradiation.
引用
- Bosch SL, van Rooijen SJ, Bökkerink GM, et al. Acute toxicity and surgical complications after preoperative (chemo)radiation therapy for rectal cancer in patients with inflammatory bowel disease. Radiother Oncol. 2017. PMID: 28291546. doi:10.1016/j.radonc.2017.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。